



Capital Advisors Group's Debt Market Update

Full Year 2023

[Please click here for disclosure information:](#) Our research is for personal, non-commercial use only. You may not copy, distribute or modify content without prior written authorization from Capital Advisors Group. All contents © Copyright 2024 Capital Advisors Group, Inc. All rights reserved.


Commentary – Full Year 2023

The venture debt markets got off to a historically tepid start in 2023 and continued its slow pace through Q2. According to Pitchbook, despite this slow start, the market rebounded significantly in the second half of 2023. Ultimately, total funding ended up at a four-year low while total deal count skidded to a five-year low. As we review debt as a percentage of the venture equity markets in 2023, the 2023 debt total of \$30.2B rose to more than 17% of total equity financings which is in line with the trailing 5-year historical average of 16.86%. The debt markets were severely impacted in the first half of 2023 by the venture banking crisis. While the numbers in the second half demonstrate a rebound in the market, a deeper dive illustrates the continued impact felt by earlier stage companies. Lending to later stage companies drove the second half rebound while average early-stage deal size declined. Anecdotally, conservatism among earlier stage lenders reigned in 2023 as venture bank consolidation slowed the normal course of business and equity markets pulled back.

US Venture Capital and Debt Activity



US Venture Debt Activity



Information and data sources include PitchBook Data as of 12/31/2023 and other publicly available data from parties that Capital Advisors Group has engaged with on historical debt transactions and is suited for general informational purposes only. Capital Advisors Group makes no representation or warranty regarding the accuracy or completeness of the data. [Please click here for disclosure information](#); Our research is for personal, non-commercial use only. You may not copy, distribute or modify content without prior written authorization from Capital Advisors Group. All contents © Copyright 2024 Capital Advisors Group, Inc. All rights reserved.

Healthcare

In 2023, healthcare debt financing (in total deal value) retreated to lows not seen since 2016. As is often the case with earlier stage debt financing, the debt market tends to follow the equity markets. This reality is even more stark for healthcare companies that face long term R&D requirements and regulatory hurdles before generating revenue. In some cases, healthcare venture lenders will require some equity to be raised for companies to qualify for debt financing. In 2023, with equity more difficult to raise, lenders had to pass on deals where equity would likely have been available in prior years. According to Pitchbook, deal value and deal count in life sciences specifically dropped to pre-pandemic levels which played a role in reduced output in the debt market.

We expect this trend to continue until venture and IPO markets recover. As we look ahead to 2024, sentiment is growing that the IPO market will recover in healthcare, which may prompt additional venture equity activity, and thus spur the debt markets to respond in kind.


Technology

In the tech sector, venture debt deal volume declined for the second year in a row. The number of deals completed in 2023 was down 33% relative to 2022. The dollar value for tech sector venture debt deals completed in 2023 was down as well, 27% year-over-year.


Interestingly, deal size increased on average from \$20.2M in 2022 to \$22.1M in 2023. This ~10% increase in average deal size is all the more surprising against a backdrop where venture equity investors are deploying less capital and valuations are facing headwinds.

In light of the challenges that tech companies had in raising both venture equity and venture debt, many have started to turn towards other forms of capital. For example, asset-based lenders who made loans against accounts receivable, inventory, equipment, and other assets reported a sharp uptick in demand.

US Healthcare Venture Debt Activity



Technology Venture Debt Activity



Information and data sources include PitchBook Data as of 12/31/2023 and other publicly available data from parties that Capital Advisors Group has engaged with on historical debt transactions and is suited for general informational purposes only. Capital Advisors Group makes no representation or warranty regarding the accuracy or completeness of the data. [Please click here for disclosure information](#); Our research is for personal, non-commercial use only. You may not copy, distribute or modify content without prior written authorization from Capital Advisors Group. All contents © Copyright 2024 Capital Advisors Group, Inc. All rights reserved.

Why Consider Venture Debt



Runway Extension

Extends runway required to hit important milestones prior to next equity raise, which may help drive a higher valuation.



Less Dilutive Growth Capital

Enables continued investment in growth, while minimizing the dilution associated with raising equity.



Enhance Liquidity

Provides a cash cushion, which may act as "insurance" if it takes longer than anticipated to reach the next milestone or raise the next equity round.



Acquisition Financing

Reduces operating burn to provide more cash for potential acquisitions.



No Board Seat Requirements




Brings on a significant capital partner without impacting current board dynamic.

End-to-End Transaction Support

From initial query to cash in hand, we develop your strategy, evaluate potential lenders, solicit bids, and help you source the most favorable deals.



Sample Transactions

 Term Loan \$70,000,000	 Term Loan \$80,000,000	 Asset-Based Revolver & Term Loan \$65,000,000
---	--	---

Recently completed debt deals. For our clients' confidentiality, only those clients who have authorized us to use their name and financing information in our marketing materials are listed. Clients listed do not necessarily endorse or approve of the debt advisory services provided by Capital Advisors Group.

Key Team Members

Since 2003, we have worked side-by-side with emerging growth companies to help obtain the best terms and conditions for debt transactions ranging from \$5M to more than \$200M.



Stefan Spazek
EVP – Director of Debt Placement



Ryan McCarthy
Managing Director



Kerry Hu
AVP – Financial Analyst

[Please click here for disclosure information](#): Our research is for personal, non-commercial use only. You may not copy, distribute or modify content without prior written authorization from Capital Advisors Group. All contents © Copyright 2024 Capital Advisors Group, Inc. All rights reserved.

Disclaimer

Any projections, forecasts and estimates, including without limitation any statement using "expect" or "believe" or any variation of either term or a similar term, contained herein are forward-looking statements and are based upon certain current assumptions, beliefs and expectations that Capital Advisors Group, Inc. ("CAG") considers reasonable. Forward-looking statements are necessarily speculative in nature, and it can be expected that some or all of the assumptions or beliefs underlying the forward-looking statements will not materialize or will vary significantly from actual results or outcomes. Some important factors that could cause actual results or outcomes to differ materially from those in any forward-looking statements include, among others, changes in interest rates and general economic conditions in the U.S. and globally, changes in the liquidity available in the market, changes and volatility in the value of the U.S. dollar, market volatility and distressed credit markets, and other market, financial or legal uncertainties. Consequently, the inclusion of forward-looking statements herein should not be regarded as a representation by CAG or any other person or entity of the outcomes or results that will be achieved by following any recommendations contained herein. While the forward-looking statements in this presentation reflect estimates, expectations and beliefs, they are not guarantees of future performance or outcomes. CAG has no obligation to update or otherwise revise any forward-looking statements, including any revisions to reflect changes in economic conditions or other circumstances arising after the date hereof or to reflect the occurrence of events (whether anticipated or unanticipated), even if the underlying assumptions do not come to fruition. Opinions expressed herein are subject to change without notice and do not necessarily take into account the particular investment objectives, financial situations or particular needs of all investors. This presentation is intended for informational purposes only and should not be construed as a solicitation or offer with respect to the purchase or sale of any security. Further, certain information set forth above may be based upon one or more third-party sources. No assurance can be given as to the accuracy of such third-party information. CAG assumes no responsibility for investigating, verifying or updating any information reported from any source. Photocopying or redistributing this presentation in any form is strictly prohibited. This presentation is a confidential document and may not be provided or disclosed to any parties other than the intended recipient(s) without the prior written consent of CAG. FundIQ® and CounterpartyIQ® are registered trademarks of Capital Advisors Group. Debt Advisors Group is a division of Capital Advisors Group, Inc. that provides debt finance consulting services. Debt Advisors Group is not part of Capital Advisors Group, Inc.'s investment advisory business.

All contents © copyright 2024 Capital Advisors Group, Inc. All rights reserved.